cyclic guanosine monophosphate-adenosine monophosphate profile

c-GMP-AMP : A cyclic purine dinucleotide that consists of AMP and GMP units cyclised via 3',5'-linkages. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

2'-3'-cGAMP : A cyclic purine dinucleotide that consists of AMP and GMP units cyclised via 3',5'- and 2',5'-linkages respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	135471108
CHEMBL ID	4449584
CHEBI ID	71580
SCHEMBL ID	19940046
MeSH ID	M0588853
PubMed CID	135564529
CHEMBL ID	4465054
CHEBI ID	75947
SCHEMBL ID	17325409
SCHEMBL ID	24649405
MeSH ID	M0588853

Synonym
cgamp
3',5'-cyclic gmp-amp
2-amino-9-[(2r,3r,3as,7ar,9r,10r,10as,14ar)-9-(6-amino-9h-purin-9-yl)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2h,7h-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecin-2-yl]-1,9-dihydro-6h-purin-6-one
CHEBI:71580
c-gmp-amp
3',3'-cgamp
c[g(3',5')pa(3',5')p]
3'3'-cyclic guanosine monophosphate-adenosine monophosphate
CS-3892
4bw ,
2-amino-9-[(2r,3r,3as,5r,7ar,9r,10r,10as,12r,14ar)-9-(6-amino-9h-purin-9-yl)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2h,7h-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecin-2-yl]-1,9-dihydro-6h-purin-6-one
HY-12512
AKOS030526925
849214-04-6
CHEMBL4449584 ,
SCHEMBL19940046
2-amino-9-((2r,3r,3as,7ar,9r,10r,10as,14ar)-9-(6-amino-9h-purin-9-yl)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2h,7h-difuro[3,2-d:3',2'-j][1,3,7,9]tetraoxa[2,8]diphosphacyclododecin-2-yl)-3,9-dihydro-6h-purin-6-one
3',3' cgamp; c-gmp-amp; c[g(3',5')pa(3',5')p]
2-amino-9-[(1s,6r,8r,9r,10s,15r,17r,18r)-17-(6-aminopurin-9-yl)-3,9,12,18-tetrahydroxy-3,12-dioxo-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.3.0.06,10]octadecan-8-yl]-1h-purin-6-one
Q27139728
EX-A2911
cgamp; c-gpap
C76713
bdbm50509401
DTXSID401045334
1sy ,
2',3'-cgamp
cgamp(2'-5')
cyclic gp(2'-5')ap(3'-5')
C20640 ,
cyclic guanosine monophosphate-adenosine monophosphate
c[g(2',5')pa(3',5')p]
CHEBI:75947 ,
2'-3'-cgamp
1441190-66-4
2-amino-9-[(5r,7r,8r,12ar,14r,15r,15as,16r)-14-(6-amino-9h-purin-9-yl)-2,10,15,16-tetrahydroxy-2,10-dioxidooctahydro-12h-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]-1,9-dihydro-6h-purin-6-one
cyclic (guanosine-(2'->5')-monophosphate-adenosine-(3'->5')-monophosphate)
2'-o,5'-o-[(adenosine-3'-o,5'-o-diyl)bisphosphinico]guanosine
2',5'-3',5'-cgamp
2'3'-cyclic guanosine monophosphate-adenosine monophosphate
SCHEMBL17325409
c(g(2',5')pa(3',5')p)
j3.180.146j ,
unii-552y49k43e
552y49k43e ,
2'-o,5'-o-((adenosine-3'-o,5'-o-diyl)bisphosphinico)guanosine
2'-guanylic acid, adenylyl-(3'->5')-, cyclic nucleotide
2-amino-9-((5r,7r,8r,12ar,14r,15r,15as,16r)-14-(6-amino-9h-purin-9-yl)-2,10,15,16-tetrahydroxy-2,10-dioxidooctahydro-12h-5,8-methanofuro(3,2-l)(1,3,6,9,11,2,10)pentaoxadiphosphacyclotetradecin-7-yl)-1,9-dihydro-6h-purin-6-one
2-amino-9-((2r,5r,7r,8r,10s,12ar,14r,15r,15as,16r)-14-(6-amino-9h-purin-9-yl)-2,10,15,16-tetrahydroxy-2,10-dioxidooctahydro-12h-5,8-methanofuro(3,2-l)(1,3,6,9,11,2,10)pentaoxadiphosphacyclotetradecin-7-yl)-3,9-dihydro-6h-purin-6-one
2-amino-9-((1r,6r,8r,9r,10s,15r,17r,18r)-8-(6-amino-9h-purin-9-yl)-3,9,12,18-tetrahydroxy-3,12-dioxido-2,4,7,11,13,16-hexaoxa-3,12-diphosphatricyclo(13.2.1.06,10)octadec-17-yl)-1,9-dihydro-6h-purin-6-one
6h-purin-6-one, 2-amino-9-((5r,7r,8r,12ar,14r,15r,15as,16r)-14-(6-amino-9h-purin-9-yl)octahydro-2,10,15,16-tetrahydroxy-2,10-dioxido-5,8-methano-12h-furo(3,2-l)-1,3,6,9,11,2,10-pentaoxadiphosphacyclot etradecin-7-yl)-1,9-dihydro-
5'-o,2'-o-(3',5'-dideoxyadenosine-3',5'-diylbis(oxy(hydroxyphosphinylidene)))guanosine
2'3'-cgamp
AC-33623
cyclic [g(2',5')pa(3',5')p]
gtpl9207
CHEMBL4465054 ,
bdbm50506263
2',3'-cgamp sodium salt, >=98% (hplc)
2',3' cgamp; c-gmp-amp; c[g(2',5')pa(3',5')p]
2-amino-9-[(2r,5r,7r,8r,10s,12ar,14r,15r,15as,16r)-14-(6-amino-9h-purin-9-yl)-2,10,15,16-tetrahydroxy-2,10-dioxidooctahydro-12h-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]-3,9-dihydro-6h-purin-6-one
Q17143195
SCHEMBL24649405
2-amino-9-[(1r,6r,8r,9r,10s,15r,17r,18r)-8-(6-aminopurin-9-yl)-3,9,12,18-tetrahydroxy-3,12-dioxo-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1h-purin-6-one
2-amino-9-[(1r,6r,8r,9r,10s,15r,17r,18r)-8-(6-amino-9h-purin-9-yl)-3,9,12,18-tetrahydroxy-3,12-dioxido-2,4,7,11,13,16-hexaoxa-3,12-diphosphatricyclo[13.2.1.06,10]octadec-17-yl]-1,9-dihydro-6h-purin-6-one
A901660
2/'3/'-cgamp
2-3-cgamp
2'-3'-cyclic gmp-amp;2',3'-cgamp
PD039600
(1r,6r,8r,9r,10s,15r,17r,18r)-17-(2-amino-6-oxo-6,9-dihydro-1h-purin-9-yl)-8-(6-amino-9h-purin-9-yl)-3,9,12,18-tetrahydroxy-2,4,7,11,13,16-hexaoxa-3,12-diphosphatricyclo[13.2.1.0,octadecane-3,12-dione
AKOS040732256

Excerpt	Reference
" The orally bioavailable modulators of gap junctions meclofenamate and tonabersat break this paracrine loop, and we provide proof-of-principle that these drugs could be used to treat established brain metastasis."	( Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Boire, A; Chen, Q; Cross, JR; Er, EE; Jacob, L; Jin, X; Lopez-Soto, A; Massagué, J; Patwa, R; Shah, H; Valiente, M; Xu, K, 2016)
" However, natural CDNs are hydrophilic small molecules with negative charges and are susceptible to enzymatic degradation, leading to low bioavailability in target tissues yet unwanted toxicities and narrow therapeutic windows."	( STING activation in cancer immunotherapy. Lin, S; Su, T; Valerie, K; Wang, XY; Zhang, Y; Zhu, G, 2019)

Class	Description
adenyl ribonucleotide	A purine riboncleotide where adenine is the purine.
cyclic purine dinucleotide
guanyl ribonucleotide	A purine ribonucleotide where the purine is guanine.
cyclic purine dinucleotide
guanyl ribonucleotide	A purine ribonucleotide where the purine is guanine.
adenyl ribonucleotide	A purine riboncleotide where adenine is the purine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Cytosolic DNA-sensing pathway	0	1
STING pathway in Kawasaki-like disease and COVID-19	0	4
Mitochondrial immune response to SARS-CoV-2	8	5

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Stimulator of interferon genes protein	Homo sapiens (human)	IC50 (µMol)	0.0036	0.0018	0.0036	0.0055	AID1528522; AID1905855
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Stimulator of interferon genes protein	Mus musculus (house mouse)	EC50 (µMol)	0.0200	0.0200	0.0200	0.0200	AID1575508
Stimulator of interferon genes protein	Homo sapiens (human)	EC50 (µMol)	50.4309	0.0058	1.3611	7.2000	AID1541395; AID1541396; AID1541397; AID1541399; AID1541400; AID1814337; AID1814342; AID1814344; AID1814346; AID1814347; AID1852608; AID1852613
Stimulator of interferon genes protein	Homo sapiens (human)	Kd	0.7810	0.0038	1.3131	5.2000	AID1546606; AID1575505; AID1575507; AID1861452
Stimulator of interferon genes protein	Mus musculus (house mouse)	EC50 (µMol)	18.8000	0.0200	0.0200	0.0200	AID1714249
Stimulator of interferon genes protein	Mus musculus (house mouse)	Kd	0.0000	0.0000	1.4225	3.5000	AID1905864
Stimulator of interferon genes protein	Homo sapiens (human)	EC50 (µMol)	13.0984	0.0058	1.3611	7.2000	AID1528518; AID1541395; AID1541396; AID1541397; AID1541399; AID1541400; AID1714251; AID1714253; AID1714255; AID1749739; AID1816900; AID1852608; AID1852613; AID1861453; AID1905663
Stimulator of interferon genes protein	Homo sapiens (human)	Kd	9.1608	0.0038	1.3131	5.2000	AID1546606; AID1575505; AID1575509; AID1861452; AID1905860
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
protein complex oligomerization	Stimulator of interferon genes protein	Homo sapiens (human)
autophagosome assembly	Stimulator of interferon genes protein	Homo sapiens (human)
activation of innate immune response	Stimulator of interferon genes protein	Homo sapiens (human)
pattern recognition receptor signaling pathway	Stimulator of interferon genes protein	Homo sapiens (human)
positive regulation of defense response to virus by host	Stimulator of interferon genes protein	Homo sapiens (human)
cytoplasmic pattern recognition receptor signaling pathway	Stimulator of interferon genes protein	Homo sapiens (human)
positive regulation of macroautophagy	Stimulator of interferon genes protein	Homo sapiens (human)
positive regulation of protein binding	Stimulator of interferon genes protein	Homo sapiens (human)
positive regulation of type I interferon production	Stimulator of interferon genes protein	Homo sapiens (human)
positive regulation of interferon-beta production	Stimulator of interferon genes protein	Homo sapiens (human)
cellular response to interferon-beta	Stimulator of interferon genes protein	Homo sapiens (human)
innate immune response	Stimulator of interferon genes protein	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Stimulator of interferon genes protein	Homo sapiens (human)
regulation of inflammatory response	Stimulator of interferon genes protein	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Stimulator of interferon genes protein	Homo sapiens (human)
protein complex oligomerization	Stimulator of interferon genes protein	Homo sapiens (human)
defense response to virus	Stimulator of interferon genes protein	Homo sapiens (human)
positive regulation of type I interferon-mediated signaling pathway	Stimulator of interferon genes protein	Homo sapiens (human)
reticulophagy	Stimulator of interferon genes protein	Homo sapiens (human)
protein localization to endoplasmic reticulum	Stimulator of interferon genes protein	Homo sapiens (human)
cellular response to exogenous dsRNA	Stimulator of interferon genes protein	Homo sapiens (human)
cellular response to organic cyclic compound	Stimulator of interferon genes protein	Homo sapiens (human)
antiviral innate immune response	Stimulator of interferon genes protein	Homo sapiens (human)
cGAS/STING signaling pathway	Stimulator of interferon genes protein	Homo sapiens (human)
proton transmembrane transport	Stimulator of interferon genes protein	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Interferon regulatory factor 3	Homo sapiens (human)
cytoplasmic pattern recognition receptor signaling pathway	Interferon regulatory factor 3	Homo sapiens (human)
apoptotic process	Interferon regulatory factor 3	Homo sapiens (human)
DNA damage response	Interferon regulatory factor 3	Homo sapiens (human)
signal transduction involved in regulation of gene expression	Interferon regulatory factor 3	Homo sapiens (human)
lipopolysaccharide-mediated signaling pathway	Interferon regulatory factor 3	Homo sapiens (human)
positive regulation of type I interferon production	Interferon regulatory factor 3	Homo sapiens (human)
positive regulation of interferon-alpha production	Interferon regulatory factor 3	Homo sapiens (human)
positive regulation of interferon-beta production	Interferon regulatory factor 3	Homo sapiens (human)
toll-like receptor 4 signaling pathway	Interferon regulatory factor 3	Homo sapiens (human)
TRIF-dependent toll-like receptor signaling pathway	Interferon regulatory factor 3	Homo sapiens (human)
MDA-5 signaling pathway	Interferon regulatory factor 3	Homo sapiens (human)
regulation of apoptotic process	Interferon regulatory factor 3	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Interferon regulatory factor 3	Homo sapiens (human)
innate immune response	Interferon regulatory factor 3	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon regulatory factor 3	Homo sapiens (human)
regulation of inflammatory response	Interferon regulatory factor 3	Homo sapiens (human)
defense response to virus	Interferon regulatory factor 3	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon regulatory factor 3	Homo sapiens (human)
positive regulation of type I interferon-mediated signaling pathway	Interferon regulatory factor 3	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon regulatory factor 3	Homo sapiens (human)
macrophage apoptotic process	Interferon regulatory factor 3	Homo sapiens (human)
programmed necrotic cell death	Interferon regulatory factor 3	Homo sapiens (human)
cellular response to virus	Interferon regulatory factor 3	Homo sapiens (human)
cGAS/STING signaling pathway	Interferon regulatory factor 3	Homo sapiens (human)
positive regulation of cytokine production involved in inflammatory response	Interferon regulatory factor 3	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Interferon regulatory factor 3	Homo sapiens (human)
immune system process	Interferon regulatory factor 3	Homo sapiens (human)
protein complex oligomerization	Stimulator of interferon genes protein	Homo sapiens (human)
autophagosome assembly	Stimulator of interferon genes protein	Homo sapiens (human)
activation of innate immune response	Stimulator of interferon genes protein	Homo sapiens (human)
pattern recognition receptor signaling pathway	Stimulator of interferon genes protein	Homo sapiens (human)
positive regulation of defense response to virus by host	Stimulator of interferon genes protein	Homo sapiens (human)
cytoplasmic pattern recognition receptor signaling pathway	Stimulator of interferon genes protein	Homo sapiens (human)
positive regulation of macroautophagy	Stimulator of interferon genes protein	Homo sapiens (human)
positive regulation of protein binding	Stimulator of interferon genes protein	Homo sapiens (human)
positive regulation of type I interferon production	Stimulator of interferon genes protein	Homo sapiens (human)
positive regulation of interferon-beta production	Stimulator of interferon genes protein	Homo sapiens (human)
cellular response to interferon-beta	Stimulator of interferon genes protein	Homo sapiens (human)
innate immune response	Stimulator of interferon genes protein	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Stimulator of interferon genes protein	Homo sapiens (human)
regulation of inflammatory response	Stimulator of interferon genes protein	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Stimulator of interferon genes protein	Homo sapiens (human)
protein complex oligomerization	Stimulator of interferon genes protein	Homo sapiens (human)
defense response to virus	Stimulator of interferon genes protein	Homo sapiens (human)
positive regulation of type I interferon-mediated signaling pathway	Stimulator of interferon genes protein	Homo sapiens (human)
reticulophagy	Stimulator of interferon genes protein	Homo sapiens (human)
protein localization to endoplasmic reticulum	Stimulator of interferon genes protein	Homo sapiens (human)
cellular response to exogenous dsRNA	Stimulator of interferon genes protein	Homo sapiens (human)
cellular response to organic cyclic compound	Stimulator of interferon genes protein	Homo sapiens (human)
antiviral innate immune response	Stimulator of interferon genes protein	Homo sapiens (human)
cGAS/STING signaling pathway	Stimulator of interferon genes protein	Homo sapiens (human)
proton transmembrane transport	Stimulator of interferon genes protein	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Stimulator of interferon genes protein	Homo sapiens (human)
proton channel activity	Stimulator of interferon genes protein	Homo sapiens (human)
protein kinase binding	Stimulator of interferon genes protein	Homo sapiens (human)
ubiquitin protein ligase binding	Stimulator of interferon genes protein	Homo sapiens (human)
cyclic-di-GMP binding	Stimulator of interferon genes protein	Homo sapiens (human)
signaling adaptor activity	Stimulator of interferon genes protein	Homo sapiens (human)
identical protein binding	Stimulator of interferon genes protein	Homo sapiens (human)
protein homodimerization activity	Stimulator of interferon genes protein	Homo sapiens (human)
2',3'-cyclic GMP-AMP binding	Stimulator of interferon genes protein	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Stimulator of interferon genes protein	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Interferon regulatory factor 3	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Interferon regulatory factor 3	Homo sapiens (human)
DNA-binding transcription activator activity	Interferon regulatory factor 3	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Interferon regulatory factor 3	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Interferon regulatory factor 3	Homo sapiens (human)
DNA binding	Interferon regulatory factor 3	Homo sapiens (human)
DNA-binding transcription factor activity	Interferon regulatory factor 3	Homo sapiens (human)
protein binding	Interferon regulatory factor 3	Homo sapiens (human)
protein domain specific binding	Interferon regulatory factor 3	Homo sapiens (human)
identical protein binding	Interferon regulatory factor 3	Homo sapiens (human)
protein homodimerization activity	Interferon regulatory factor 3	Homo sapiens (human)
sequence-specific DNA binding	Interferon regulatory factor 3	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Interferon regulatory factor 3	Homo sapiens (human)
promoter-specific chromatin binding	Interferon regulatory factor 3	Homo sapiens (human)
protein binding	Stimulator of interferon genes protein	Homo sapiens (human)
proton channel activity	Stimulator of interferon genes protein	Homo sapiens (human)
protein kinase binding	Stimulator of interferon genes protein	Homo sapiens (human)
ubiquitin protein ligase binding	Stimulator of interferon genes protein	Homo sapiens (human)
cyclic-di-GMP binding	Stimulator of interferon genes protein	Homo sapiens (human)
signaling adaptor activity	Stimulator of interferon genes protein	Homo sapiens (human)
identical protein binding	Stimulator of interferon genes protein	Homo sapiens (human)
protein homodimerization activity	Stimulator of interferon genes protein	Homo sapiens (human)
2',3'-cyclic GMP-AMP binding	Stimulator of interferon genes protein	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Stimulator of interferon genes protein	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
Golgi membrane	Stimulator of interferon genes protein	Homo sapiens (human)
endoplasmic reticulum membrane	Stimulator of interferon genes protein	Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membrane	Stimulator of interferon genes protein	Homo sapiens (human)
Golgi membrane	Stimulator of interferon genes protein	Homo sapiens (human)
autophagosome membrane	Stimulator of interferon genes protein	Homo sapiens (human)
nucleoplasm	Stimulator of interferon genes protein	Homo sapiens (human)
mitochondrial outer membrane	Stimulator of interferon genes protein	Homo sapiens (human)
endosome	Stimulator of interferon genes protein	Homo sapiens (human)
autophagosome	Stimulator of interferon genes protein	Homo sapiens (human)
peroxisome	Stimulator of interferon genes protein	Homo sapiens (human)
endoplasmic reticulum membrane	Stimulator of interferon genes protein	Homo sapiens (human)
cytosol	Stimulator of interferon genes protein	Homo sapiens (human)
plasma membrane	Stimulator of interferon genes protein	Homo sapiens (human)
cytoplasmic vesicle membrane	Stimulator of interferon genes protein	Homo sapiens (human)
secretory granule membrane	Stimulator of interferon genes protein	Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membrane	Stimulator of interferon genes protein	Homo sapiens (human)
perinuclear region of cytoplasm	Stimulator of interferon genes protein	Homo sapiens (human)
serine/threonine protein kinase complex	Stimulator of interferon genes protein	Homo sapiens (human)
STING complex	Stimulator of interferon genes protein	Homo sapiens (human)
autophagosome	Stimulator of interferon genes protein	Homo sapiens (human)
nucleus	Interferon regulatory factor 3	Homo sapiens (human)
cytoplasm	Interferon regulatory factor 3	Homo sapiens (human)
nucleus	Interferon regulatory factor 3	Homo sapiens (human)
nucleoplasm	Interferon regulatory factor 3	Homo sapiens (human)
cytoplasm	Interferon regulatory factor 3	Homo sapiens (human)
mitochondrion	Interferon regulatory factor 3	Homo sapiens (human)
cytosol	Interferon regulatory factor 3	Homo sapiens (human)
chromatin	Interferon regulatory factor 3	Homo sapiens (human)
Golgi membrane	Stimulator of interferon genes protein	Homo sapiens (human)
endoplasmic reticulum membrane	Stimulator of interferon genes protein	Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membrane	Stimulator of interferon genes protein	Homo sapiens (human)
Golgi membrane	Stimulator of interferon genes protein	Homo sapiens (human)
autophagosome membrane	Stimulator of interferon genes protein	Homo sapiens (human)
nucleoplasm	Stimulator of interferon genes protein	Homo sapiens (human)
mitochondrial outer membrane	Stimulator of interferon genes protein	Homo sapiens (human)
endosome	Stimulator of interferon genes protein	Homo sapiens (human)
autophagosome	Stimulator of interferon genes protein	Homo sapiens (human)
peroxisome	Stimulator of interferon genes protein	Homo sapiens (human)
endoplasmic reticulum membrane	Stimulator of interferon genes protein	Homo sapiens (human)
cytosol	Stimulator of interferon genes protein	Homo sapiens (human)
plasma membrane	Stimulator of interferon genes protein	Homo sapiens (human)
cytoplasmic vesicle membrane	Stimulator of interferon genes protein	Homo sapiens (human)
secretory granule membrane	Stimulator of interferon genes protein	Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membrane	Stimulator of interferon genes protein	Homo sapiens (human)
perinuclear region of cytoplasm	Stimulator of interferon genes protein	Homo sapiens (human)
serine/threonine protein kinase complex	Stimulator of interferon genes protein	Homo sapiens (human)
STING complex	Stimulator of interferon genes protein	Homo sapiens (human)
autophagosome	Stimulator of interferon genes protein	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (136)

Assay ID	Title	Year	Journal	Article
AID1546606	Binding affinity to wild type human STING (139 to 379 residues) by ITC assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Targeting Stimulator of Interferon Genes (STING): A Medicinal Chemistry Perspective.
AID1852617	Cytotoxicity against human PBMC cells	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
AID1575507	Binding affinity to wild type human STING C-terminal domain (139 to 379 residues) expressed in Escherichia coli BL21 (DE3) by isothermal titration calorimetric method	2019	MedChemComm, Dec-01, Volume: 10, Issue:12	Interrupting cyclic dinucleotide-cGAS-STING axis with small molecules.
AID1541396	Activation of recombinant human wild-type STING expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1852607	Binding affinity to human wild type STING assessed as change in melting temperature by differential scanning fluorimetry (DSF) method	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
AID1852616	Induction of IFNalpha secretion in human PBMC incubated for 16 hrs	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
AID1541402	Activation of STING in human PBMC assessed as induction of INFgamma secretion at 12.5 uM incubated for 16 hrs by ProcartaPlex assay relative to 2'3'cGAMP	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1814339	Activation of human STING REF mutant expressed in digitonin treated HEK293T cells co-expressing IRF3-activated ISRE assessed as IRF3 reporter activation by luciferase reporter gene assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Synthesis and Biological Evaluation of Phosphoester and Phosphorothioate Prodrugs of STING Agonist 3',3'-c-Di(2'F,2'dAMP).
AID1814349	Induction of INF-alpha production in healthy human PBMC incubated for 16 hrs	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Synthesis and Biological Evaluation of Phosphoester and Phosphorothioate Prodrugs of STING Agonist 3',3'-c-Di(2'F,2'dAMP).
AID1852610	Agonist activity at human STING REF expressed in 293T cells by digitonin cell based assay	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
AID1861452	Agonist activity at wild type human STING C-terminal domain (139 to 379 residues) assessed as dissociation constant by isothermal titration calorimetry analysis	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration.
AID1575508	Inhibition of STING in mouse L929 cells assessed as reduction in cGAMP induce IFNbeta expression measured after 4 hrs by qRT-PCR	2019	MedChemComm, Dec-01, Volume: 10, Issue:12	Interrupting cyclic dinucleotide-cGAS-STING axis with small molecules.
AID1814342	Activation of wild-type human STING expressed in HEK293T cells co-expressing IRF3-activated ISRE assessed as IRF3 reporter activation measured after 30 mins by luciferase reporter gene assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Synthesis and Biological Evaluation of Phosphoester and Phosphorothioate Prodrugs of STING Agonist 3',3'-c-Di(2'F,2'dAMP).
AID1852614	Induction of IFNgamma secretion in human PBMC incubated for 16 hrs	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
AID1541400	Activation of recombinant human STING haplotype R293Q mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541395	Activation of recombinant human wild-type STING expressed in 293T cells incubated for 7 hrs in absence of digitonin A by bright Glo-luciferase reporter gene assay	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1814340	Activation of human STING QA mutant expressed in digitonin treated HEK293T cells co-expressing IRF3-activated ISRE assessed as IRF3 reporter activation by luciferase reporter gene assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Synthesis and Biological Evaluation of Phosphoester and Phosphorothioate Prodrugs of STING Agonist 3',3'-c-Di(2'F,2'dAMP).
AID1541411	Cytotoxicity against human PBMC-derived CD3-positive T cells assessed as effect on cell viability at 12.5 uM incubated for 16 hrs by Zombie-NIR staining-based flow cytometry	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541398	Activation of recombinant human STING haplotype R232H mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541403	Activation of STING in human PBMC assessed as induction of TNFalpha secretion at 12.5 uM incubated for 16 hrs by ProcartaPlex assay relative to 2'3'cGAMP	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1814341	Activation of human STING Q mutant expressed in digitonin treated HEK293T cells co-expressing IRF3-activated ISRE assessed as IRF3 reporter activation by luciferase reporter gene assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Synthesis and Biological Evaluation of Phosphoester and Phosphorothioate Prodrugs of STING Agonist 3',3'-c-Di(2'F,2'dAMP).
AID1541409	Activation of recombinant human STING haplotype G230A/R293Q mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay relative to 2'3'cGAMP	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1814346	Activation of wild-type human STING expressed in digitonin treated human THP1-Dual cells co-expressing IRF3-activated ISRE assessed as IRF3 reporter activation measured after 30 mins by luciferase reporter gene assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Synthesis and Biological Evaluation of Phosphoester and Phosphorothioate Prodrugs of STING Agonist 3',3'-c-Di(2'F,2'dAMP).
AID1852608	Agonist activity at human wild type STING expressed in 293T cells by digitonin cell based assay	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
AID1541394	Binding affinity to recombinant human wild-type STING assessed as change in melting temperature at 150 uM by SYPRO orange dye based differential scanning fluorimetric method	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1814347	Activation of wild-type human STING expressed in human THP1-Dual cells co-expressing IRF3-activated ISRE assessed as IRF3 reporter activation measured after 7 hrs by luciferase reporter gene assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Synthesis and Biological Evaluation of Phosphoester and Phosphorothioate Prodrugs of STING Agonist 3',3'-c-Di(2'F,2'dAMP).
AID1814344	Activation of wild-type human STING expressed in HEK293T cells co-expressing IRF3-activated ISRE assessed as IRF3 reporter activation measured after 7 hrs by luciferase reporter gene assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Synthesis and Biological Evaluation of Phosphoester and Phosphorothioate Prodrugs of STING Agonist 3',3'-c-Di(2'F,2'dAMP).
AID1861454	Agonist activity at human STING H232 variant assessed as dissociation constant	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration.
AID1814353	Induction of TNF-alpha production in healthy human PBMC incubated for 16 hrs	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Synthesis and Biological Evaluation of Phosphoester and Phosphorothioate Prodrugs of STING Agonist 3',3'-c-Di(2'F,2'dAMP).
AID1814351	Induction of INF-gamma production in healthy human PBMC incubated for 16 hrs	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Synthesis and Biological Evaluation of Phosphoester and Phosphorothioate Prodrugs of STING Agonist 3',3'-c-Di(2'F,2'dAMP).
AID1541405	Ratio of EC50 for recombinant human wild-type STING expressed in 293T cells in absence of digitonin A to EC50 for recombinant human wild-type STING expressed in 293T cells in presence of digitonin A	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541399	Activation of recombinant human STING haplotype G230A/R293Q mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1852609	Agonist activity at human STING HAQ expressed in 293T cells by digitonin cell based assay	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
AID1541407	Activation of recombinant human STING haplotype R71H/G230A/R293Q mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay relative to 2'3'cGAMP	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541406	Activation of recombinant human wild-type STING expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay relative to 2'3'cGAMP	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541408	Activation of recombinant human STING haplotype R232H mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay relative to 2'3'cGAMP	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541401	Cytotoxicity against human PBMC-derived monocytes assessed as CD3-negative CD14 positive monocyte viability at 12.5 uM incubated for 16 hrs by Zombie-NIR staining-based flow cytometry relative to control	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1546605	Binding affinity to human STING H232 mutant by ITC assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Targeting Stimulator of Interferon Genes (STING): A Medicinal Chemistry Perspective.
AID1814338	Activation of human STING HAQ mutant expressed in digitonin treated HEK293T cells co-expressing IRF3-activated ISRE assessed as IRF3 reporter activation by luciferase reporter gene assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Synthesis and Biological Evaluation of Phosphoester and Phosphorothioate Prodrugs of STING Agonist 3',3'-c-Di(2'F,2'dAMP).
AID1575505	Binding affinity to human STING expressed in Escherichia coli by isothermal titration calorimetric method	2019	MedChemComm, Dec-01, Volume: 10, Issue:12	Interrupting cyclic dinucleotide-cGAS-STING axis with small molecules.
AID1852613	Agonist activity at human wild type full length STING expressed in 293T cells incubated for 7 hrs by luciferase/cell based assay	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
AID1541410	Activation of recombinant human STING haplotype R293Q mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay relative to 2'3'cGAMP	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541387	Activation of STING in human PBMC assessed as induction of INFalpha secretion at 12.5 uM incubated for 16 hrs by ProcartaPlex assay relative to 2'3'cGAMP	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1852615	Induction of TNFalpha secretion in human PBMC incubated for 16 hrs	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
AID1814337	Activation of wild-type human STING expressed in digitonin treated HEK293T cells co-expressing IRF3-activated ISRE assessed as IRF3 reporter activation by luciferase reporter gene assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Synthesis and Biological Evaluation of Phosphoester and Phosphorothioate Prodrugs of STING Agonist 3',3'-c-Di(2'F,2'dAMP).
AID1852612	Agonist activity at human STING Q expressed in 293T cells by digitonin cell based assay	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
AID1852611	Agonist activity at human STING AQ expressed in 293T cells by digitonin cell based assay	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
AID1541397	Activation of recombinant human STING haplotype R71H/G230A/R293Q mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1905863	Binding affinity to human STING HAQ variant assessed as half life by Surface plasmon resonance assay	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
AID1528528	Agonist activity at STING in human PBMC cells assessed as increase in IL6 production at 139 uM measured after 4 hrs by ELISA	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Design, Synthesis, and Biological Evaluation of Amidobenzimidazole Derivatives as Stimulator of Interferon Genes (STING) Receptor Agonists.
AID1528529	Agonist activity at STING in human PBMC cells assessed as increase in IFNbeta mRNA level at 69.6 uM measured after 4 hrs by qRT-PCR analysis	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Design, Synthesis, and Biological Evaluation of Amidobenzimidazole Derivatives as Stimulator of Interferon Genes (STING) Receptor Agonists.
AID1852608	Agonist activity at human wild type STING expressed in 293T cells by digitonin cell based assay	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
AID1905885	Antitumor immunity in mouse MC38 cells implanted in C57BL/6J mouse assessed as increase in TNF-alpha level in injected tumor at 100 to 500 ug,IT administrated in right flank on day 0 measured after 4 hrs by mesoscale assay	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
AID1852615	Induction of TNFalpha secretion in human PBMC incubated for 16 hrs	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
AID1541408	Activation of recombinant human STING haplotype R232H mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay relative to 2'3'cGAMP	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1546606	Binding affinity to wild type human STING (139 to 379 residues) by ITC assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Targeting Stimulator of Interferon Genes (STING): A Medicinal Chemistry Perspective.
AID1601375	Antitumor activity against mouse B16-OVA cells implanted in mouse assessed as tumour regression in contralateral flank at 10 ug administered intratumorally on day 6, 9 and 12 post implantation	2019	Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20	Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy.
AID1541406	Activation of recombinant human wild-type STING expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay relative to 2'3'cGAMP	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541399	Activation of recombinant human STING haplotype G230A/R293Q mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1905854	Displacement of radiolabeled [3H]-2',3'-cGAMP from human STING HAQ variant incubated for 2 hrs by scintillation counting method	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
AID1816900	Binding affinity to human STING incubated for 60 mins measured by competitive TR-FRET assay	2021	Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10	Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.
AID1575505	Binding affinity to human STING expressed in Escherichia coli by isothermal titration calorimetric method	2019	MedChemComm, Dec-01, Volume: 10, Issue:12	Interrupting cyclic dinucleotide-cGAS-STING axis with small molecules.
AID1714253	Activation of STING in human THP-1-Dual cells assessed as induction of type I IFNs by measuring stimulation of NF-kappaB pathway incubated for 48 hrs by luciferase reporter gene assay
AID1816905	Stability in human serum assessed as half life measured upto 120 mins by LC-MS/MS analysis	2021	Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10	Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.
AID1816904	Stability in rat serum assessed as half life measured upto 120 mins by LC-MS/MS analysis	2021	Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10	Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.
AID1528521	Cytotoxicity against STING knockout human THP1 cells assessed as reduction in cell viability by MTS assay	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Design, Synthesis, and Biological Evaluation of Amidobenzimidazole Derivatives as Stimulator of Interferon Genes (STING) Receptor Agonists.
AID1861452	Agonist activity at wild type human STING C-terminal domain (139 to 379 residues) assessed as dissociation constant by isothermal titration calorimetry analysis	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration.
AID1852609	Agonist activity at human STING HAQ expressed in 293T cells by digitonin cell based assay	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
AID1905879	Antitumor immunity in mouse MC38 cells implanted in C57BL/6J mouse assessed as increase in IL-6 level in injected tumor at 100 to 500 ug,IT administrated in right flank on day 0 measured after 4 hrs by mesoscale assay	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
AID1905856	Binding affinity to human STING HAQ variant assessed as melting temperature by thermal shift assay	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
AID1905865	Binding affinity to wild type mouse STING assessed as half life by Surface plasmon resonance assay	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
AID1541400	Activation of recombinant human STING haplotype R293Q mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1852614	Induction of IFNgamma secretion in human PBMC incubated for 16 hrs	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
AID1541394	Binding affinity to recombinant human wild-type STING assessed as change in melting temperature at 150 uM by SYPRO orange dye based differential scanning fluorimetric method	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541411	Cytotoxicity against human PBMC-derived CD3-positive T cells assessed as effect on cell viability at 12.5 uM incubated for 16 hrs by Zombie-NIR staining-based flow cytometry	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1905862	Binding affinity to human STING HAQ variant assessed as dissociation constant by Surface plasmon resonance assay	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
AID1905861	Binding affinity to wild type human STING assessed as half life by Surface plasmon resonance assay	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
AID1541403	Activation of STING in human PBMC assessed as induction of TNFalpha secretion at 12.5 uM incubated for 16 hrs by ProcartaPlex assay relative to 2'3'cGAMP	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541407	Activation of recombinant human STING haplotype R71H/G230A/R293Q mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay relative to 2'3'cGAMP	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1905864	Binding affinity to wild type mouse STING assessed as dissociation constant by Surface plasmon resonance assay	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
AID1905860	Binding affinity to wild type human STING assessed as dissociation constant by Surface plasmon resonance assay	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
AID1714243	Stability in presence of nuclease P1 assessed as parent compound remaining level at 7 ug incubated for 2 hrs by HPLC analysis
AID1905663	Agonist activity at STING in human wild-type THP1-Dual cells co-expressing ISRE reporter assessed as IRF-mediated immune response incubated for 24 hrs by QUANTI Luc based microplate reader method	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Development of Potent Immune Modulators Targeting Stimulator of Interferon Genes Receptor.
AID1905858	Agonist activity at STING HAQ variant in human THP1 cell assessed as maximum human INF-beta production incubated for 5 hrs by mesoscale assay relative to control	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
AID1905875	Antitumor activity against mouse MC38 cells implanted in C57BL/6J mouse assessed as tumor growth inhibition in non-injected left flank at 100 ug,IT administrated in left flank on day 0,3,7 and 10 measured after 15 days	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
AID1541398	Activation of recombinant human STING haplotype R232H mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1905894	Antitumor immunity in mouse MC38 cells implanted in C57BL/6J mouse assessed as increase in IFN-gamma level in injected tumor at 100 to 500 ug,IT administrated in right flank on day 0 measured after 4 hrs by ELISA	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
AID1541396	Activation of recombinant human wild-type STING expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1861453	Agonist activity at STING (unknown origin)	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration.
AID1905664	Cytotoxicity against human wild type THP1-Dual cells assessed as residual cell viability by CellTiter96 Aqueous One Solution Cell Proliferation Assay	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Development of Potent Immune Modulators Targeting Stimulator of Interferon Genes Receptor.
AID1905889	Agonist activity at STING HAQ variant in mouse BMDC cells assessed as maximum mouse INF-beta production incubated for 5 hrs by ELISA relative to control	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
AID1714242	Induction of type I IFN production in mouse RAW-Lucia ISG-KO-STING cells at 0.08 to 60 ug/ml incubated for 48 hrs by luciferase reporter gene assay
AID1575509	Binding affinity to human C-terminal STING domain (139 to 378 residues) by microscale thermophoresis method	2019	MedChemComm, Dec-01, Volume: 10, Issue:12	Interrupting cyclic dinucleotide-cGAS-STING axis with small molecules.
AID1714249	Activation of STING in mouse RAW-Lucia ISG cells assessed as induction of type I IFNs stimulation by measuring induction of IRF pathway incubated for 48 hrs by luciferase reporter gene assay
AID1905857	Binding affinity to wild type human STING assessed as melting temperature by thermal shift assay	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
AID1528519	Induction of IRF3 pathway in STING knockout human THP1 cells measured after 20 hrs by luciferase reporter gene assay	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Design, Synthesis, and Biological Evaluation of Amidobenzimidazole Derivatives as Stimulator of Interferon Genes (STING) Receptor Agonists.
AID1816903	Agonist activity at STING HAQ mutant in human THP-1 dual cells incubated for 20 hrs by luciferase reporter gene assay	2021	Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10	Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.
AID1528518	Agonist activity at STING in human THP1 cells assessed as stimulation of IRF3 pathway measured after 20 hrs by luciferase reporter gene assay	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Design, Synthesis, and Biological Evaluation of Amidobenzimidazole Derivatives as Stimulator of Interferon Genes (STING) Receptor Agonists.
AID1541397	Activation of recombinant human STING haplotype R71H/G230A/R293Q mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541409	Activation of recombinant human STING haplotype G230A/R293Q mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay relative to 2'3'cGAMP	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1601371	Antitumor activity against mouse B16-OVA cells implanted in mouse assessed as tumour regression in injected flank at 10 ug administered intratumorally on day 6, 9 and 12 post implantation	2019	Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20	Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy.
AID1528522	Inhibition of anti 6His antibody-labeled terbium cryptate binding to human wild-type full-length 6His-tagged d2-labeled STING measured after 4 hrs by HTRF assay	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Design, Synthesis, and Biological Evaluation of Amidobenzimidazole Derivatives as Stimulator of Interferon Genes (STING) Receptor Agonists.
AID1528520	Cytotoxicity against human THP1 cells assessed as reduction in cell viability by MTS assay	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Design, Synthesis, and Biological Evaluation of Amidobenzimidazole Derivatives as Stimulator of Interferon Genes (STING) Receptor Agonists.
AID1714255	Activation of STING in human blood assessed as induction of type I IFNs incubated for 18 to 20 hrs by QUANTI-Blue assay
AID1541405	Ratio of EC50 for recombinant human wild-type STING expressed in 293T cells in absence of digitonin A to EC50 for recombinant human wild-type STING expressed in 293T cells in presence of digitonin A	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1852612	Agonist activity at human STING Q expressed in 293T cells by digitonin cell based assay	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
AID1852616	Induction of IFNalpha secretion in human PBMC incubated for 16 hrs	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
AID1905855	Displacement of radiolabeled [3H]-2',3'-cGAMP from wild type human STING incubated for 2 hrs by scintillation counting method	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
AID1861454	Agonist activity at human STING H232 variant assessed as dissociation constant	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration.
AID1714247	Stability in presence of snake venom phosphodiesterase assessed as parent compound remaining level at 7 ug incubated for 2 hrs by HPLC analysis
AID1905884	Antitumor immunity in mouse MC38 cells implanted in C57BL/6J mouse assessed as increase in IFN-beta level in injected tumor at 100 to 500 ug,IT administrated in right flank on day 0 measured after 4 hrs by ELISA	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
AID1816902	Agonist activity at human STING R232 mutant transfected in HEK293T cells co-expressing ISRE Nano-Luc incubated for 20 hrs by luciferase reporter gene assay	2021	Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10	Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.
AID1905859	Agonist activity at STING HAQ variant in human THP1 cell assessed as increase in human INF-beta production incubated for 5 hrs by mesoscale assay	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
AID1852611	Agonist activity at human STING AQ expressed in 293T cells by digitonin cell based assay	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
AID1852613	Agonist activity at human wild type full length STING expressed in 293T cells incubated for 7 hrs by luciferase/cell based assay	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
AID1528531	Agonist activity at STING in human PBMC cells assessed as increase in IL6 mRNA level at 69.6 uM measured after 4 hrs by qRT-PCR analysis	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Design, Synthesis, and Biological Evaluation of Amidobenzimidazole Derivatives as Stimulator of Interferon Genes (STING) Receptor Agonists.
AID1714257	Stability in presence of ENPP1 ( unknown origin) assessed as half life by HPLC analysis
AID1528524	Agonist activity at STING in human PBMC cells assessed as increase in IFNbeta release at 1.39 to 139 uM measured after 4 hrs by ELISA	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Design, Synthesis, and Biological Evaluation of Amidobenzimidazole Derivatives as Stimulator of Interferon Genes (STING) Receptor Agonists.
AID1714251	Activation of STING in human THP-1-Dual cells assessed as induction of type I IFNs by measuring stimulation of IRF pathway incubated for 48 hrs by luciferase reporter gene assay
AID1528530	Agonist activity at STING in human PBMC cells assessed as increase in CXCL10 mRNA level at 69.6 uM measured after 4 hrs by qRT-PCR analysis	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Design, Synthesis, and Biological Evaluation of Amidobenzimidazole Derivatives as Stimulator of Interferon Genes (STING) Receptor Agonists.
AID1852607	Binding affinity to human wild type STING assessed as change in melting temperature by differential scanning fluorimetry (DSF) method	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
AID1541387	Activation of STING in human PBMC assessed as induction of INFalpha secretion at 12.5 uM incubated for 16 hrs by ProcartaPlex assay relative to 2'3'cGAMP	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1905888	Agonist activity at STING HAQ variant in mouse BMDC cells assessed as increase in mouse INF-beta production incubated for 5 hrs by ELISA	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
AID1905876	Antitumor activity against mouse MC38 cells implanted in C57BL/6J mouse assessed as tumor growth inhibition in non-injected left flank at 50 ug,IT administrated in left flank on day 0,3,7 and 10 measured after 15 days	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
AID1816901	Agonist activity at human STING R232 mutant transfected in HEK293T cells co-expressing ISRE Nano-Luc incubated for 30 mins in presence of digitonin by luciferase reporter gene assay	2021	Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10	Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.
AID1541410	Activation of recombinant human STING haplotype R293Q mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay relative to 2'3'cGAMP	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1905659	Induction of STING dependent immune response in human wild type THP1-Dual cells co-expressing ISRE reporter assessed as normalized luciferase gene expression by measuring relative luciferase units at 50 uM incubated for 24 hrs by QUANTI Luc based micropla	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Development of Potent Immune Modulators Targeting Stimulator of Interferon Genes Receptor.
AID1541395	Activation of recombinant human wild-type STING expressed in 293T cells incubated for 7 hrs in absence of digitonin A by bright Glo-luciferase reporter gene assay	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541402	Activation of STING in human PBMC assessed as induction of INFgamma secretion at 12.5 uM incubated for 16 hrs by ProcartaPlex assay relative to 2'3'cGAMP	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1546605	Binding affinity to human STING H232 mutant by ITC assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Targeting Stimulator of Interferon Genes (STING): A Medicinal Chemistry Perspective.
AID1749739	Binding affinity to 6His-tagged human STING measured after 3 hrs by HTRF assay	2021	Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3	Structure-Activity Relationship Study of Amidobenzimidazole Analogues Leading to Potent and Systemically Administrable Stimulator of Interferon Gene (STING) Agonists.
AID1852610	Agonist activity at human STING REF expressed in 293T cells by digitonin cell based assay	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
AID1852617	Cytotoxicity against human PBMC cells	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
AID1541401	Cytotoxicity against human PBMC-derived monocytes assessed as CD3-negative CD14 positive monocyte viability at 12.5 uM incubated for 16 hrs by Zombie-NIR staining-based flow cytometry relative to control	2019	Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23	Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1601376	Antitumor activity against mouse B16-OVA cells implanted in mouse assessed as higher number of mouse cured of tumors at 10 ug administered intratumorally on day 6, 9 and 12 post implantation	2019	Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20	Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy.
AID1346267	Human transmembrane protein 173 (Other pattern recognition receptors)	2013	Molecular cell, Jul-25, Volume: 51, Issue:2	Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	161 (49.24)	24.3611
2020's	166 (50.76)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Trials	1 (0.30%)	5.53%
Reviews	2 (33.33%)	6.00%
Reviews	39 (11.89%)	6.00%
Case Studies	0 (0.00%)	4.05%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Observational	0 (0.00%)	0.25%
Other	4 (66.67%)	84.16%
Other	288 (87.80%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
10-carboxymethyl-9-acridanone 10-carboxymethyl-9-acridanone: RN given refers to parent cpd	4.57	3	acridines
ribavirin 5'-triphosphate ribavirin 5'-triphosphate: structure given in first source. ribavirin 5'-triphosphate : A 1-ribosyltriazole that is ribavirin in which the hydroxy group at the 5'-position is replaced by a triphosphate group. It is the active metabolite of the antiviral agent ribavirin.	2.21	1	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide; ribose triphosphate	antiviral agent; drug metabolite; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor; eukaryotic initiation factor 4F inhibitor; human blood serum metabolite
vadimezan vadimezan : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 5,6-dimethyl-9-oxoxanthen-4-yl group.	4.57	3	monocarboxylic acid; xanthones	antineoplastic agent
5-aminoimidazole-4-carboxamide-1-ribofuranosyl triphosphate [no description available]	2.21	1
8-hydroxyadenosine 5'-triphosphate [no description available]	2.21	1	purine ribonucleoside 5'-triphosphate
2-chloro-atp 2-chloro-ATP: new ATP analog; relaxes mammalian gut preparations; structure	2.21	1
xanthosine 5'-triphosphate xanthosine 5'-triphosphate: RN given refers to parent cpd	2.21	1	purine ribonucleoside 5'-triphosphate; xanthosine 5'-phosphate	Escherichia coli metabolite; mouse metabolite
8-azidoadenosine 5'-triphosphate [no description available]	2.21	1
6-thioinosine-5'-triphosphate [no description available]	2.21	1	organic molecule
mangostin mangostin: xanthone from rind of Garcinia mangostana Linn. fruit. alpha-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3 and 6, a methoxy group at position 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antioxidant, antimicrobial and antitumour activities.	4.24	2	aromatic ether; phenols; xanthones	antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite
vx680 [no description available]	3.31	1	N-arylpiperazine
bx795 BX795: structure in first source	3.31	1	ureas
6-thioguanosine 5'-triphosphate [no description available]	2.21	1
cyclic diadenosine phosphate cyclic di-AMP : A cyclic purine dinucleotide that is the 3',5'-cyclic dimer of AMP.	4.28	4	adenyl ribonucleotide; cyclic purine dinucleotide	Mycoplasma genitalium metabolite
2-fluoro-araatp [no description available]	2.21	1
mrt67307 MRT67307: IKK (IκB(inhibitor of NF-κB (nuclear factor κB)) kinase) family inhibitor; structure in first source	3.31	1	aromatic amine
inosine triphosphate Inosine Triphosphate: Inosine 5'-(tetrahydrogen triphosphate). An inosine nucleotide containing three phosphate groups esterified to the sugar moiety. Synonym: IRPPP.	2.21	1	inosine phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
bis(3',5')-cyclic diguanylic acid [no description available]	4.97	5	cyclic purine dinucleotide; guanyl ribonucleotide	immunomodulator; signalling molecule
8-hydroxyguanosine triphosphate [no description available]	2.21	1
guanosine 5'-o-(1-thiotriphosphate) [no description available]	2.21	1
gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.	2.31	1	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
adenine [no description available]	2.17	1	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
melatonin [no description available]	2.6	1	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger
nitrites Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)	3.06	1	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species	human metabolite
phosphoric acid phosphoric acid: concise etchant is 37% H3PO4. phosphoric acid : A phosphorus oxoacid that consists of one oxo and three hydroxy groups joined covalently to a central phosphorus atom.	2.31	1	phosphoric acids	algal metabolite; fertilizer; human metabolite; NMR chemical shift reference compound; solvent
amlexanox amlexanox: SRA-A antagonist;structure given in first source. amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.	2.21	1	monocarboxylic acid; pyridochromene	anti-allergic agent; anti-ulcer drug; non-steroidal anti-inflammatory drug
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	2.13	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
meclofenamic acid Meclofenamic Acid: A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.. meclofenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis.	2.13	1	aminobenzoic acid; organochlorine compound; secondary amino compound	analgesic; anticonvulsant; antineoplastic agent; antipyretic; antirheumatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
metoprolol Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.. metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.	3.06	1	aromatic ether; propanolamine; secondary alcohol; secondary amino compound	antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; geroprotector; xenobiotic
hydroxyproline Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.. hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.	2.15	1	4-hydroxyproline; L-alpha-amino acid zwitterion	human metabolite; mouse metabolite; plant metabolite
carbon tetrachloride Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.	2.15	1	chlorocarbon; chloromethanes	hepatotoxic agent; refrigerant
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	2.15	1	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2.11	1	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
cytidine [no description available]	2.31	1	cytidines	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
asparagine Asparagine: A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed). asparagine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 2-amino-2-oxoethyl group.	2.15	1	amino acid zwitterion; asparagine; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
proflavine Proflavine: Topical antiseptic used mainly in wound dressings.. 3,6-diaminoacridine : An aminoacridine that is acridine that is substituted by amino groups at positions 3 and 6. A slow-acting bacteriostat that is effective against many Gram-positive bacteria (but ineffective against spores), its salts were formerly used for treatment of burns and infected wounds.	2.15	1	aminoacridines	antibacterial agent; antiseptic drug; carcinogenic agent; chromophore; intercalator
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	2.15	1	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
cyclopentane Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.	2.25	1	cycloalkane; cyclopentanes; volatile organic compound	non-polar solvent
2-aminopurine 2-Aminopurine: A purine that is an isomer of ADENINE (6-aminopurine).. aminopurine : Any purine having at least one amino substituent.. 2-aminopurine : The parent compound of the 2-aminopurines, comprising a purine core carrying an amino substituent at the 2-position.	2.1	1	2-aminopurines; nucleobase analogue	antimetabolite
alpha-aminopyridine alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.	2.21	1
podophyllotoxin Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.	2.6	1	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	2.15	1	dialdehyde	biomarker
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	2.15	1	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
clodronic acid Clodronic Acid: A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification.. clodronic acid : An organochlorine compound that is methylene chloride in which both hydrogens are replaced by phosphonic acid groups. It inhibits bone resorption and soft tissue calcification, and is used (often as the disodium salt tetrahydrate) as an adjunct in the treatment of severe hypercalcaemia associated with malignancy, and in the management of osteolytic lesions and bone pain associated with skeletal metastases.	2.1	1	1,1-bis(phosphonic acid); one-carbon compound; organochlorine compound	antineoplastic agent; bone density conservation agent
tetradecanoylphorbol acetate Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.	2.15	1	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.21	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	2.25	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
10-carboxymethyl-9-acridanone 10-carboxymethyl-9-acridanone: RN given refers to parent cpd	4.57	3	acridines
colforsin Colforsin: Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant COLEUS FORSKOHLII. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland.	2.13	1	acetate ester; cyclic ketone; labdane diterpenoid; organic heterotricyclic compound; tertiary alpha-hydroxy ketone; triol	adenylate cyclase agonist; anti-HIV agent; antihypertensive agent; plant metabolite; platelet aggregation inhibitor; protein kinase A agonist
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	3.06	1	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
pyrimidin-2-one beta-ribofuranoside pyrimidin-2-one beta-ribofuranoside: RN given refers to (D)-isomer; structure	2.31	1	pyrimidine ribonucleosides
2'-5'-oligoadenylate trimer 2',5'-oligoadenylate: inhibits protein synthesis in cell-free systems	3.19	1
amarogentin amarogentin: secoiridoid glycoside. amarogentin : A secoiridoid glycoside that consists of (4aS,5R,6R)-5-ethenyl-6-hydroxy-4,4a,5,6-tetrahydro-1H,3H-pyrano[3,4-c]pyran-1-one having a 2-O-[(3,3',5-trihydroxybiphenyl-2-yl)carbonyl]-beta-D-glucopyranosyl group attached at position 6 via a glycosidic linkage.	2.15	1	monosaccharide derivative; secoiridoid glycoside	EC 5.99.1.2 (DNA topoisomerase) inhibitor; metabolite
ribavirin 5'-triphosphate ribavirin 5'-triphosphate: structure given in first source. ribavirin 5'-triphosphate : A 1-ribosyltriazole that is ribavirin in which the hydroxy group at the 5'-position is replaced by a triphosphate group. It is the active metabolite of the antiviral agent ribavirin.	2.21	1	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide; ribose triphosphate	antiviral agent; drug metabolite; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor; eukaryotic initiation factor 4F inhibitor; human blood serum metabolite
vadimezan vadimezan : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 5,6-dimethyl-9-oxoxanthen-4-yl group.	7.02	12	monocarboxylic acid; xanthones	antineoplastic agent
5-aminoimidazole-4-carboxamide-1-ribofuranosyl triphosphate [no description available]	2.21	1
8-hydroxyadenosine 5'-triphosphate [no description available]	2.21	1	purine ribonucleoside 5'-triphosphate
xylose xylopyranose: structure in first source	2.6	1	D-xylose
resiquimod S 28463: structure given in first source	2.59	2	imidazoquinoline
2-chloro-atp 2-chloro-ATP: new ATP analog; relaxes mammalian gut preparations; structure	2.21	1
angiotensin ii Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).	2.13	1	amino acid zwitterion; angiotensin II	human metabolite
lapatinib [no description available]	2.31	1	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
3-nitrotyrosine 3-nitrotyrosine: RN given refers to parent cpd without isomeric designation. 3-nitrotyrosine : A nitrotyrosine comprising tyrosine having a nitro group at the 3-position on the phenyl ring.	2.11	1	2-nitrophenols; C-nitro compound; nitrotyrosine; non-proteinogenic alpha-amino acid
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	2.61	2
carboplatin [no description available]	2.21	1
leptomycin b [no description available]	2.31	1
arabinose [no description available]	2.6	1	L-arabinose	Escherichia coli metabolite; mouse metabolite
xanthosine 5'-triphosphate xanthosine 5'-triphosphate: RN given refers to parent cpd	2.21	1	purine ribonucleoside 5'-triphosphate; xanthosine 5'-phosphate	Escherichia coli metabolite; mouse metabolite
acriflavine Acriflavine: 3,6-Diamino-10-methylacridinium chloride mixt. with 3,6-acridinediamine. Fluorescent dye used as a local antiseptic and also as a biological stain. It intercalates into nucleic acids thereby inhibiting bacterial and viral replication.	2.15	1
iridoids Iridoids: A type of MONOTERPENES, derived from geraniol. They have the general form of cyclopentanopyran, but in some cases, one of the rings is broken as in the case of secoiridoid. They are different from the similarly named iridals (TRITERPENES).	2.15	1
glycosides [no description available]	2.15	1
thiobarbituric acid thiobarbituric acid: RN given refers to parent cpd. 2-thiobarbituric acid : A barbiturate, the structure of which is that of barbituric acid in which the oxygen at C-2 is replaced by sulfur.	2.11	1	barbiturates	allergen; reagent
8-azidoadenosine 5'-triphosphate [no description available]	2.21	1
orlistat Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.. orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.	2.31	1	beta-lactone; carboxylic ester; formamides; L-leucine derivative	anti-obesity agent; bacterial metabolite; EC 2.3.1.85 (fatty acid synthase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor
6-thioinosine-5'-triphosphate [no description available]	2.21	1	organic molecule
ovalbumin Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.	2.53	2
sphingosine sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.	2.66	2	sphing-4-enine	human metabolite; mouse metabolite
luteolin [no description available]	7.6	1	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
mangostin mangostin: xanthone from rind of Garcinia mangostana Linn. fruit. alpha-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3 and 6, a methoxy group at position 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antioxidant, antimicrobial and antitumour activities.	4.24	2	aromatic ether; phenols; xanthones	antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite
sphingosine 1-phosphate sphingosine 1-phosphate: RN given refers to (R-(R,S-(E)))-isomer; RN for cpd without isomeric designation not available 8/89. sphingosine 1-phosphate : A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1	2.66	2	sphingoid 1-phosphate	mouse metabolite; signalling molecule; sphingosine-1-phosphate receptor agonist; T-cell proliferation inhibitor; vasodilator agent
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	2.25	1	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
fumarates Fumarates: Compounds based on fumaric acid.. fumarate(2-) : A C4-dicarboxylate that is the E-isomer of but-2-enedioate(2-)	2.13	1	butenedioate; C4-dicarboxylate	human metabolite; metabolite; Saccharomyces cerevisiae metabolite
uroguanylin uroguanylin: amino acid sequence given in first source; stimulates intestinal guanylate cyclase; GenBank Z83746 (pig)	2.21	1
aliskiren aliskiren: orally active nonpeptidic renin inhibitor. aliskiren : A monomethoxybenzene compound having a 3-methoxypropoxy group at the 2-position and a multi-substituted branched alkyl substituent at the 4-position.	2.13	1	monocarboxylic acid amide; monomethoxybenzene	antihypertensive agent
vx680 [no description available]	3.31	1	N-arylpiperazine
saralasin Saralasin: An octapeptide analog of angiotensin II (bovine) with amino acids 1 and 8 replaced with sarcosine and alanine, respectively. It is a highly specific competitive inhibitor of angiotensin II that is used in the diagnosis of HYPERTENSION.	2.13	1	oligopeptide
bafilomycin a1 bafilomycin A1: from Streptomyces griseus; structure given in first source. bafilomycin A1 : The most used of the bafilomycins, a family of toxic macrolide antibiotics derived from Streptomyces griseus.	2.15	1	cyclic hemiketal; macrolide antibiotic; oxanes	apoptosis inducer; autophagy inhibitor; bacterial metabolite; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor; ferroptosis inhibitor; fungicide; potassium ionophore; toxin
beta-escin [no description available]	2.25	1
tonabersat tonabersat: potential antimigraine agent; structure in first source	2.13	1
bx795 BX795: structure in first source	3.68	2	ureas
phosphoramidite phosphoramidite: structure in first source. phosphoramidite : A compound with the general formula (RO)2PNR2. Phosphoramidites can be regarded as phosphites that have an NR2 instead of an OH group, or as amides of phosphorous acid.	2.31	1
6-thioguanosine 5'-triphosphate [no description available]	2.21	1
ribose ribopyranose : The pyranose form of ribose.	2.41	1	D-ribose; ribopyranose
cyclic diadenosine phosphate cyclic di-AMP : A cyclic purine dinucleotide that is the 3',5'-cyclic dimer of AMP.	4.04	3	adenyl ribonucleotide; cyclic purine dinucleotide	Mycoplasma genitalium metabolite
d-arg-dmt-lys-phe-nh2 [no description available]	3.06	1
ceruletide Ceruletide: A specific decapeptide obtained from the skin of Hila caerulea, an Australian amphibian. Caerulein is similar in action and composition to CHOLECYSTOKININ. It stimulates gastric, biliary, and pancreatic secretion; and certain smooth muscle. It is used in paralytic ileus and as diagnostic aid in pancreatic malfunction.. ceruletide : A decapeptide comprising 5-oxoprolyl, glutamyl, aspartyl, O-sulfotyrosyl, threonyl, glycyl, tryptopyl, methionyl, aspartyl and phenylalaninamide residues in sequence. Found in the skins of certain Australian amphibians, it is an analogue of the gastrointestinal peptide hormone cholecystokinin and stimulates gastric, biliary, and pancreatic secretion. It is used in cases of paralysis of the intestine (paralytic ileus) and as a diagnostic aid in pancreatic malfunction.	2.17	1	oligopeptide	diagnostic agent; gastrointestinal drug
oligonucleotides [no description available]	2.55	2
adenosine kinase Adenosine Kinase: An enzyme that catalyzes the formation of ADP plus AMP from adenosine plus ATP. It can serve as a salvage mechanism for returning adenosine to nucleic acids. EC 2.7.1.20.	2.31	1
2-fluoro-araatp [no description available]	2.21	1
mrt67307 MRT67307: IKK (IκB(inhibitor of NF-κB (nuclear factor κB)) kinase) family inhibitor; structure in first source	3.31	1	aromatic amine
apatinib apatinib: reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters; structure in first source	2.31	1
plecanatide plecanatide: A uroguanylin analog and guanylate cyclase (GC-C receptor) agonist that activates receptors on gut epithelial cells to maintain barrier function, mucus production, and suppress inflammation. It is used in the treatment of chronic idiopathic constipation and other gastrointestinal disorders.	2.21	1
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone: an interleukin-1beta converting enzyme (ICE)-like protease inhibitor	2.31	1
tro 40303 3,5-seco-4-norcholestan-5-one oxime-3-ol: a cardioprotective agent; structure in first source	3.06	1
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	3.06	1
cyclic gmp Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.	6.97	21	3',5'-cyclic purine nucleotide; guanyl ribonucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
guanosine triphosphate Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.	3.82	2	guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
inosine triphosphate Inosine Triphosphate: Inosine 5'-(tetrahydrogen triphosphate). An inosine nucleotide containing three phosphate groups esterified to the sugar moiety. Synonym: IRPPP.	2.21	1	inosine phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
sildenafil citrate Sildenafil Citrate: A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.. sildenafil citrate : The citrate salt of sildenafil.	2.15	1	citrate salt	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
bis(3',5')-cyclic diguanylic acid [no description available]	6.73	16	cyclic purine dinucleotide; guanyl ribonucleotide	immunomodulator; signalling molecule
8-hydroxyguanosine triphosphate [no description available]	2.21	1
guanosine 5'-o-(1-thiotriphosphate) [no description available]	2.21	1
concanavalin a Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.	2.6	1

Condition	Relationship Strength	Studies	Trials
Autoimmune Disease [description not available]	5.59	6	0
Benign Neoplasms [description not available]	10.03	42	0
Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.	5.59	6	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	10.03	42	0
Malignant Melanoma [description not available]	3.49	6	0
B16 Melanoma [description not available]	3.56	7	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	3.49	6	0
Carcinoma, Squamous Cell of Head and Neck [description not available]	2.69	2	0
Cancer of Head [description not available]	2.31	1	0
Squamous Cell Carcinoma of Head and Neck The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.	2.69	2	0
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	2.31	1	0
Cancer of Pancreas [description not available]	3.43	5	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	3.43	5	0
Degenerative Diseases, Central Nervous System [description not available]	3.5	2	0
Innate Inflammatory Response [description not available]	8.01	25	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	8.01	25	0
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	3.5	2	0
Complications of Diabetes Mellitus [description not available]	2.31	1	0
Impotence [description not available]	2.31	1	0
Erectile Dysfunction The inability in the male to have a PENILE ERECTION due to psychological or organ dysfunction.	2.31	1	0
Blood Poisoning [description not available]	2.31	1	0
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	2.31	1	0
HIV Coinfection [description not available]	3.28	5	0
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	3.28	5	0
Presbycusis Gradual bilateral hearing loss associated with aging that is due to progressive degeneration of cochlear structures and central auditory pathways. Hearing loss usually begins with the high frequencies then progresses to sounds of middle and low frequencies.	2.9	2	0
2019 Novel Coronavirus Disease [description not available]	3.07	3	0
Infections, Pseudomonas [description not available]	2.31	1	0
Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS.	2.31	1	0
Bowel Diseases, Inflammatory [description not available]	3.33	1	0
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	3.33	1	0
Inflammatory Bowel Diseases Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.	3.33	1	0
Infections, Orthomyxoviridae [description not available]	3.18	4	0
Orthomyxoviridae Infections Virus diseases caused by the ORTHOMYXOVIRIDAE.	3.18	4	0
African Swine Fever A sometimes fatal ASFIVIRUS infection of pigs, characterized by fever, cough, diarrhea, hemorrhagic lymph nodes, and edema of the gallbladder. It is transmitted between domestic swine by direct contact, ingestion of infected meat, or fomites, or mechanically by biting flies or soft ticks (genus Ornithodoros).	2.9	2	0
Non-communicable Chronic Diseases [description not available]	3.33	1	0
Viral Diseases [description not available]	5.19	9	0
Virus Diseases A general term for diseases caused by viruses.	5.19	9	0
Deaf Mutism [description not available]	2.6	1	0
Deafness A general term for the complete loss of the ability to hear from both ears.	2.6	1	0
Periodontitis, Acute Nonsuppurative [description not available]	2.6	1	0
Periapical Cyst [description not available]	2.6	1	0
Dental Granuloma [description not available]	2.6	1	0
Periapical Periodontitis Inflammation of the PERIAPICAL TISSUE. It includes general, unspecified, or acute nonsuppurative inflammation. Chronic nonsuppurative inflammation is PERIAPICAL GRANULOMA. Suppurative inflammation is PERIAPICAL ABSCESS.	2.6	1	0
Blood Pressure, Low [description not available]	2.6	1	0
Hypotension Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.	2.6	1	0
Acute Ischemic Stroke [description not available]	2.6	1	0
Ischemic Stroke Stroke due to BRAIN ISCHEMIA resulting in interruption or reduction of blood flow to a part of the brain. When obstruction is due to a BLOOD CLOT formed within in a cerebral blood vessel it is a thrombotic stroke. When obstruction is formed elsewhere and moved to block a cerebral blood vessel (see CEREBRAL EMBOLISM) it is referred to as embolic stroke. Wake-up stroke refers to ischemic stroke occurring during sleep while cryptogenic stroke refers to ischemic stroke of unknown origin.	7.6	1	0
Diseases, Metabolic [description not available]	2.6	1	0
Metabolic Diseases Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)	2.6	1	0
Autoimmune Diabetes [description not available]	2.21	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	4.29	15	0
Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.	2.21	1	0
Cancer of Liver [description not available]	2.21	1	0
Metastase [description not available]	3.17	4	0
Colorectal Cancer [description not available]	2.21	1	0
Liver Neoplasms Tumors or cancer of the LIVER.	2.21	1	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	3.17	4	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.21	1	0
Asthma, Bronchial [description not available]	2.66	2	0
Eosinophilia, Pulmonary [description not available]	2.21	1	0
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	2.66	2	0
Pulmonary Eosinophilia A condition characterized by infiltration of the lung with EOSINOPHILS due to inflammation or other disease processes. Major eosinophilic lung diseases are the eosinophilic pneumonias caused by infections, allergens, or toxic agents.	2.21	1	0
Disease Exacerbation [description not available]	2.61	2	0
Cancer of Lung [description not available]	3.07	4	0
Lung Neoplasms Tumors or cancer of the LUNG.	3.07	4	0
Ectromelia, Infectious A viral infection of mice, causing edema and necrosis followed by limb loss.	2.21	1	0
Abnormalities, Congenital, Nervous System [description not available]	2.88	3	0
Autoimmune Diseases of the Nervous System Disorders caused by cellular or humoral immune responses primarily directed towards nervous system autoantigens. The immune response may be directed towards specific tissue components (e.g., myelin) and may be limited to the central nervous system (e.g., MULTIPLE SCLEROSIS) or the peripheral nervous system (e.g., GUILLAIN-BARRE SYNDROME).	2.88	3	0
Bites [description not available]	2.55	2	0
Libman-Sacks Disease [description not available]	4.46	4	1
Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.	4.46	4	1
Anoxia-Ischemia, Brain [description not available]	2.25	1	0
Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.	2.25	1	0
Hypoxia-Ischemia, Brain A disorder characterized by a reduction of oxygen in the blood combined with reduced blood flow (ISCHEMIA) to the brain from a localized obstruction of a cerebral artery or from systemic hypoperfusion. Prolonged hypoxia-ischemia is associated with ISCHEMIC ATTACK, TRANSIENT; BRAIN INFARCTION; BRAIN EDEMA; COMA; and other conditions.	2.25	1	0
Herpes Simplex Virus Infection [description not available]	2.84	3	0
Herpes Simplex A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)	2.84	3	0
Infections, Helicobacter [description not available]	2.25	1	0
Helicobacter Infections Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.	2.25	1	0
Grippe [description not available]	2.25	1	0
Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.	2.25	1	0
Diathesis [description not available]	4.07	2	0
Break-Bone Fever [description not available]	2.25	1	0
Dengue An acute febrile disease transmitted by the bite of AEDES mosquitoes infected with DENGUE VIRUS. It is self-limiting and characterized by fever, myalgia, headache, and rash. SEVERE DENGUE is a more virulent form of dengue.	2.25	1	0
Experimental Neoplasms [description not available]	2.94	3	0
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	2.9	3	0
Local Neoplasm Recurrence [description not available]	2.25	1	0
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	2.9	3	0
Angiogenesis, Pathologic [description not available]	2.86	3	0
Breast Cancer [description not available]	2.58	2	0
Breast Neoplasms Tumors or cancer of the human BREAST.	2.58	2	0
Hereditary Autoinflammation Diseases [description not available]	2.25	1	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	2.57	2	0
ALS - Amyotrophic Lateral Sclerosis [description not available]	2.31	1	0
Amyotrophic Lateral Sclerosis A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)	2.31	1	0
Bird Pox [description not available]	2.25	1	0
Diseases of Immune System [description not available]	3.23	1	0
Immune System Diseases Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both.	3.23	1	0
Infections, Poxviridae [description not available]	3.23	1	0
Allergic Encephalomyelitis [description not available]	2.31	1	0
Vaccinia The cutaneous and occasional systemic reactions associated with vaccination using smallpox (variola) vaccine.	2.85	3	0
Hyperlipemia [description not available]	2.31	1	0
Hyperlipidemias Conditions with excess LIPIDS in the blood.	2.31	1	0
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	2.9	3	0
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	3.23	1	0
Liver Dysfunction [description not available]	3.23	1	0
Liver Diseases Pathological processes of the LIVER.	3.23	1	0
Neurovisceral Storage Disease with Vertical Supranuclear Ophthalmoplegia [description not available]	2.31	1	0
Niemann-Pick Disease, Type C An autosomal recessive lipid storage disorder that is characterized by accumulation of CHOLESTEROL and SPHINGOMYELINS in cells of the VISCERA and the CENTRAL NERVOUS SYSTEM. Type C (or C1) and type D are allelic disorders caused by mutation of the NPC1 gene, which encodes a protein that mediates intracellular cholesterol transport from LYSOSOMES. Clinical signs include hepatosplenomegaly and chronic neurological symptoms. Type D is a variant in people with a Nova Scotia ancestry.	2.31	1	0
Kaposi Sarcoma [description not available]	2.31	1	0
Sarcoma, Kaposi A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause.	2.31	1	0
Benign Neoplasms, Brain [description not available]	2.86	3	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.86	3	0
Cirrhosis, Liver [description not available]	2.15	1	0
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	2.15	1	0
Cytomegalic Inclusion Disease [description not available]	2.15	1	0
Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.	2.15	1	0
Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.	2.57	2	0
Bacterial Infections, Gram-Negative [description not available]	2.17	1	0
Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.	2.17	1	0
Cancer of Colon [description not available]	3.5	2	0
Colonic Neoplasms Tumors or cancer of the COLON.	3.5	2	0
Acute Edematous Pancreatitis [description not available]	2.17	1	0
Acute Disease Disease having a short and relatively severe course.	2.17	1	0
Pancreatitis INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.	2.17	1	0
Genital Herpes [description not available]	2.17	1	0
Herpes Genitalis Infection of the genitals (GENITALIA) with HERPES SIMPLEX VIRUS in either the males or the females.	2.17	1	0
Hepatitis B Virus Infection [description not available]	2.59	2	0
Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.	7.59	2	0
Circoviridae Infections Virus diseases caused by the CIRCOVIRIDAE.	2.17	1	0
Infections, Listeria [description not available]	2.21	1	0
Carcinoma, Thymic [description not available]	2.21	1	0
Cancer of the Thymus [description not available]	2.21	1	0
Thymoma A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (From Stedman, 25th ed)	2.21	1	0
Thymus Neoplasms Tumors or cancer of the THYMUS GLAND.	2.21	1	0
AIDS, Simian [description not available]	2.21	1	0
Fatty Liver, Nonalcoholic [description not available]	2.21	1	0
Diabetes Mellitus, Adult-Onset [description not available]	2.21	1	0
Insulin Sensitivity [description not available]	2.21	1	0
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	2.21	1	0
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	2.21	1	0
Non-alcoholic Fatty Liver Disease Fatty liver finding without excessive ALCOHOL CONSUMPTION.	2.21	1	0
Cognitive Decline [description not available]	2.21	1	0
Acute Confusional Senile Dementia [description not available]	2.21	1	0
Cognition Disorders Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.	2.21	1	0
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.21	1	0
Cognitive Dysfunction Diminished or impaired mental and/or intellectual function.	2.21	1	0
Colitis, Mucous [description not available]	2.21	1	0
Colonic Inertia Symptom characterized by the passage of stool once a week or less.	2.21	1	0
Constipation Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.	2.21	1	0
Irritable Bowel Syndrome A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.	2.21	1	0
Cancer of Ovary [description not available]	2.21	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.21	1	0
Adenocarcinoma, Basal Cell [description not available]	2.1	1	0
Carcinoma, Non-Small Cell Lung [description not available]	2.1	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.1	1	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.1	1	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	2.1	1	0
Infections, Chlamydia [description not available]	2.1	1	0
Chlamydia Infections Infections with bacteria of the genus CHLAMYDIA.	2.1	1	0
Genetic Diseases [description not available]	3.48	1	1
Symptom Cluster [description not available]	3.48	1	1
Syndrome A characteristic symptom complex.	3.48	1	1
Genetic Diseases, Inborn Diseases that are caused by genetic mutations present during embryo or fetal development, although they may be observed later in life. The mutations may be inherited from a parent's genome or they may be acquired in utero.	3.48	1	1
Neurogenic Inflammation Inflammation caused by an injurious stimulus of peripheral neurons and resulting in release of neuropeptides which affect vascular permeability and help initiate proinflammatory and immune reactions at the site of injury.	2.11	1	0
B Virus Infection [description not available]	2.11	1	0
DNA Virus Infections Diseases caused by DNA VIRUSES.	2.13	1	0
ST Elevated Myocardial Infarction [description not available]	3.06	1	0
Injury, Myocardial Reperfusion [description not available]	3.06	1	0
ST Elevation Myocardial Infarction A clinical syndrome defined by MYOCARDIAL ISCHEMIA symptoms; persistent elevation in the ST segments of the ELECTROCARDIOGRAM; and release of BIOMARKERS of myocardial NECROSIS (e.g., elevated TROPONIN levels). ST segment elevation in the ECG is often used in determining the treatment protocol (see also NON-ST ELEVATION MYOCARDIAL INFARCTION).	3.06	1	0
Active Hyperemia [description not available]	2.15	1	0
Hyperemia The presence of an increased amount of blood in a body part or an organ leading to congestion or engorgement of blood vessels. Hyperemia can be due to increase of blood flow into the area (active or arterial), or due to obstruction of outflow of blood from the area (passive or venous).	2.15	1	0

cyclic guanosine monophosphate-adenosine monophosphate

Description

Cross-References

Synonyms (72)

Bioavailability

Drug Classes (3)

Pathways (3)

Protein Targets (3)

Inhibition Measurements

Activation Measurements

Biological Processes (42)

Molecular Functions (21)

Ceullar Components (20)

Bioassays (136)

Research

Studies (327)

Study Types

cyclic guanosine monophosphate-adenosine monophosphate

Description

Cross-References

Synonyms (72)

Bioavailability

Drug Classes (3)

Pathways (3)

Protein Targets (3)

Inhibition Measurements

Activation Measurements

Biological Processes (42)

Molecular Functions (21)

Ceullar Components (20)

Bioassays (136)

Research

Studies (327)

Study Types

Related Drugs (113)

Related Conditions (171)